Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Xevinapant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005443/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN
    Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005018/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant
    Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant

    01 Oct 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/debiopharm-launches-trilynx---a-large-scale-phase-iii-clinical-trial-to-further-evaluate-xevinapant-in-the-treatment-of-head--neck-cancer-301143930.html

    PRNEWSWIRE
    01 Oct 2020
    Share Share